Literature DB >> 25412711

Use of antidepressants among community-dwelling persons with Alzheimer's disease: a nationwide register-based study.

Marja-Liisa Laitinen1, Eija Lönnroos2, J Simon Bell1, Piia Lavikainen1, Raimo Sulkava2, Sirpa Hartikainen1.   

Abstract

BACKGROUND: Antidepressants are used to treat depression and behavioral symptoms in Alzheimer's disease (AD), although their effectiveness has been questioned and evidence about the risks is accumulating. The objective of this study was to compare antidepressant use among persons with and without AD in Finland.
METHODS: The Social Insurance Institution of Finland (SII) identified all persons with a verified diagnosis of AD in Finland on December 31, 2005. For each person with AD a comparison person matched for age, sex and region of residence was also identified. Data on reimbursed drug purchases in 2005 were extracted from the Finnish National Prescription Register (FNPR). Conditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for antidepressant use.
RESULTS: The study sample comprised of 28,089 matched pairs of persons with and without AD (mean age 80.0 SD 6.8, 32.2% men).The prevalence of antidepressant use was higher among persons with AD than without AD (29.4% vs. 10.7%, OR = 3.54; 95% CI: 3.38, 3.70). Among the persons with AD, the prevalence of antidepressant use increased with time since AD diagnosis but not with age. Overall, 90.4% of antidepressant users with AD were co-dispensed anti-dementia drugs.
CONCLUSIONS: The antidepressant use was three times more prevalent among persons with AD compared to those without. Though the antidepressant selection was largely consistent with clinical practice guidelines, the high prevalence of use warrants further investigation given the uncertain effectiveness and adverse events related to these drugs.

Entities:  

Keywords:  antidepressive agents

Mesh:

Substances:

Year:  2014        PMID: 25412711     DOI: 10.1017/S1041610214002427

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  8 in total

1.  Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer's disease.

Authors:  Reetta Kettunen; Heidi Taipale; Anna-Maija Tolppanen; Antti Tanskanen; Jari Tiihonen; Sirpa Hartikainen; Marjaana Koponen
Journal:  Eur J Clin Pharmacol       Date:  2018-11-09       Impact factor: 2.953

2.  Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer's Disease.

Authors:  Yijun Pan; Kotaro Omori; Izna Ali; Masanori Tachikawa; Tetsuya Terasaki; Kim L R Brouwer; Joseph A Nicolazzo
Journal:  Mol Pharm       Date:  2018-08-22       Impact factor: 4.939

3.  Factors associated with antidepressant use in residents with and without dementia in Australian aged care facilities.

Authors:  Henna Hiltunen; Edwin C K Tan; Jenni Ilomäki; Sarah N Hilmer; Renuka Visvanathan; Tina Emery; Leonie Robson; Mary J Jones; Sirpa Hartikainen; J Simon Bell
Journal:  Ther Adv Drug Saf       Date:  2016-04-01

Review 4.  Efficacy of Antidepressants for Depression in Alzheimer's Disease: Systematic Review and Meta-Analysis.

Authors:  Vasiliki Orgeta; Naji Tabet; Ramin Nilforooshan; Robert Howard
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  IDEA intervention to prevent depressive symptoms and promote well-being in early-stage dementia: protocol for a randomised controlled feasibility study.

Authors:  Remco Tuijt; Gill Livingston; Rebecca L Gould; Rebecca Jones; Elisabet Sole Verdaguer; Vasiliki Orgeta
Journal:  BMJ Open       Date:  2018-02-08       Impact factor: 2.692

6.  Claims Data Analysis on the Dispensing of Tricyclic Antidepressants Among Patients With Dementia in Germany.

Authors:  Philipp Hessmann; Jan Zeidler; Jona Stahmeyer; Sveja Eberhard; Jonathan Vogelgsang; Mona Abdel-Hamid; Claus Wolff-Menzler; Jens Wiltfang; Bernhard Kis
Journal:  Front Pharmacol       Date:  2019-07-24       Impact factor: 5.810

7.  Effects of Tianeptine Treatment on Depression and Cognitive Function in Patients with Alzheimer's Disease: A 12-Month Retrospective Observational Study.

Authors:  José María García-Alberca; Esther Gris; Paz de la Guía; Silvia Mendoza
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

8.  Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer's disease: a nationwide matched cohort study.

Authors:  Heidi Taipale; Marjaana Koponen; Antti Tanskanen; Piia Lavikainen; Reijo Sund; Jari Tiihonen; Sirpa Hartikainen; Anna-Maija Tolppanen
Journal:  Alzheimers Res Ther       Date:  2017-08-01       Impact factor: 6.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.